IL-27: A Promising Drug Target and Biomarker (G246778)

Target Name: IL27

NCBI ID: G246778

IL-27: A Promising Drug Target and Biomarker

Interleukin 27 (IL-27), a cytokine that plays a crucial role in the regulation of immune and inflammatory responses, has recently been identified as a potential drug target and biomarker for various diseases, including cardiovascular diseases, neuroinflammatory disorders, and autoimmune diseases.

IL-27 is a cytokine that is produced by various immune cells, including T cells, B cells, and macrophages. It is a key mediator of the immune response and has been involved in the regulation of various physiological processes, including cell growth, differentiation, and inflammation.

One of the key functions of IL-27 is its role in the regulation of immune cell function. IL-27 has been shown to promote the growth and survival of immune cells, and it has been shown to play a key role in the regulation of T cell development and function.

In addition to its role in immune cell function, IL-27 has also been shown to have a variety of potential therapeutic applications. For example, IL-27 has been shown to have anti-inflammatory effects and to protect against neurodegeneration in various models, including models of multiple sclerosis and neurofibrillary tangles.

IL-27 has also been shown to have potential applications as a biomarker for various diseases. For example, studies have shown that IL-27 levels are elevated in the blood of individuals with heart failure, and that levels of IL-27 have been associated with increased risk of mortality in individuals with neurocancer.

In addition to its potential therapeutic and biomarker applications, IL-27 is also of interest as a potential drug target. Several studies have shown that IL-27 can interact with a variety of drug targets, including those involved in cell signaling, inflammation, and stress signaling.

One potential mechanism by which IL-27 may interact with drug targets is through its role as a signaling molecule. IL-27 has been shown to interact with a variety of cytokine signaling pathways, including those involved in cell growth, differentiation, and inflammation.

IL-27 has also been shown to interact with a variety of protein targets, including those involved in cell signaling, inflammation, and stress signaling. For example, studies have shown that IL-27 can interact with the protein FAK, which is involved in cell signaling and has been implicated in a variety of diseases, including cancer and neurodegeneration.

In addition to its potential role as a signaling molecule, IL-27 may also interact with other drug targets that are involved in its function as a cytokine. For example, IL-27 has been shown to interact with the protein CSF-1, which is involved in cell signaling and has been implicated in a variety of diseases, including cancer and autoimmune diseases.

Overall, IL-27 is a cytokine that has been shown to have a variety of potential therapeutic and biomarker applications. Its role as a signaling molecule and its potential interactions with drug targets make it an attractive target for further research and development. As research continues to advance, it is likely that IL-27 will become a key player in the development of new treatments for a variety of diseases.

Protein Name: Interleukin 27

Functions: Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of pro-inflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses pro-inflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replication

More Common Targets